Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Footnotes
  • References
  • Version history
Article has an altmetric score of 4

See more details

Posted by 6 X users
1 readers on Mendeley
  • Article usage
  • Citations to this article (0)

Advertisement

Editor's note Open Access | 10.1172/JCI162885

Imaging infection amid inflammation

Patrick C. Seed

Find articles by Seed, P. in: JCI | PubMed | Google Scholar |

Published September 15, 2022 - More info

Published in Volume 132, Issue 18 on September 15, 2022
J Clin Invest. 2022;132(18):e162885. https://doi.org/10.1172/JCI162885.
© 2022 Seed et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published September 15, 2022 - Version history
View PDF

Related article:

Imaging sensitive and drug-resistant bacterial infection with [11C]-trimethoprim
Iris K. Lee, … , Robert K. Doot, Mark A. Sellmyer
Iris K. Lee, … , Robert K. Doot, Mark A. Sellmyer
Clinical Research and Public Health Infectious disease Article has an altmetric score of 9

Imaging sensitive and drug-resistant bacterial infection with [11C]-trimethoprim

  • Text
  • PDF
Abstract

BACKGROUND Several molecular imaging strategies can identify bacterial infections in humans. PET affords the potential for sensitive infection detection deep within the body. Among PET-based approaches, antibiotic-based radiotracers, which often target key bacterial-specific enzymes, have considerable promise. One question for antibiotic radiotracers is whether antimicrobial resistance (AMR) reduces specific accumulation within bacteria, diminishing the predictive value of the diagnostic test.METHODS Using a PET radiotracer based on the antibiotic trimethoprim (TMP), [11C]-TMP, we performed in vitro uptake studies in susceptible and drug-resistant bacterial strains and whole-genome sequencing (WGS) in selected strains to identify TMP resistance mechanisms. Next, we queried the NCBI database of annotated bacterial genomes for WT and resistant dihydrofolate reductase (DHFR) genes. Finally, we initiated a first-in-human protocol of [11C]-TMP in patients infected with both TMP-sensitive and TMP-resistant organisms to demonstrate the clinical feasibility of the tool.RESULTS We observed robust [11C]-TMP uptake in our panel of TMP-sensitive and -resistant bacteria, noting relatively variable and decreased uptake in a few strains of P. aeruginosa and E. coli. WGS showed that the vast majority of clinically relevant bacteria harbor a WT copy of DHFR, targetable by [11C]-TMP, and that despite the AMR, these strains should be “imageable.” Clinical imaging of patients with [11C]-TMP demonstrated focal radiotracer uptake in areas of infectious lesions.CONCLUSION This work highlights an approach to imaging bacterial infection in patients, which could affect our understanding of bacterial pathogenesis as well as our ability to better diagnose infections and monitor response to therapy.TRIAL REGISTRATION ClinicalTrials.gov NCT03424525.FUNDING Institute for Translational Medicine and Therapeutics, Burroughs Wellcome Fund, NIH Office of the Director Early Independence Award (DP5-OD26386), and University of Pennsylvania NIH T32 Radiology Research Training Grant (5T32EB004311-12).

Authors

Iris K. Lee, Daniel A. Jacome, Joshua K. Cho, Vincent Tu, Anthony J. Young, Tiffany Dominguez, Justin D. Northrup, Jean M. Etersque, Hsiaoju S. Lee, Andrew Ruff, Ouniol Aklilu, Kyle Bittinger, Laurel J. Glaser, Daniel Dorgan, Denis Hadjiliadis, Rahul M. Kohli, Robert H. Mach, David A. Mankoff, Robert K. Doot, Mark A. Sellmyer

×

A common clinical conundrum is localizing sites of deep infection and differentiating sterile from nonsterile inflammation. Distinguishing infection and other forms of inflammation is highly consequential; this affects subsequent diagnostic testing, interventional procedures, prognoses, and the medical therapies employed, including the use of antiinfectives.

PET imaging already aids in localizing sites of concern for infection and differentiating them from sterile inflammation based on the biochemical and metabolic activity of the sites of interest. The commonly used PET radiotracer 2-deoxy-2-[18F]fluoro-D-glucose (FDG) is taken up in tissue sites with increased metabolic activity, suggestive of sites of inflammation that may include infection (1). In particular, microbes and white blood cells typically have higher glucose utilization than surrounding tissues. However, human and microbial cells uptake the labeled glucose for metabolism, and the tracer with PET cannot always definitively differentiate between areas with and without infection. Other metabolically active sites without infection or inflammation, as found in cancer, organ injury, or inherently metabolically demanding organs, such as the liver and heart, also readily uptake the tracers such as FDG. PET tracers exclusively taken up by microbes would facilitate differentiation of infection and sterile inflammation, aiding in clinical decision-making.

In this issue of the JCI, Lee, Jacome, and colleagues extended their investigation of an antibiotic-based radiotracer, [13C]-trimethoprim, combined with PET to localize the site of potential infection and to distinguish sterile and nonsterile inflammation (2). Trimethoprim, a clinically used antibiotic, selectively binds to bacterial dihydrofolate reductase (DHFR) to block folate metabolism and impair nucleotide synthesis, thus arresting bacterial growth. When labeled for PET imaging, the accumulated trimethoprim serves as a beacon from the site of an infection.

The authors performed a pilot study involving human participants in which [11C]-trimethoprim PET imaging localized to sites of presumed and biopsy-proven infection, which was also confirmed by other imaging modalities, including CT and MRI. The authors further demonstrated that, compared with FDG, the trimethoprim-based radiotracer did not visually enhance sites of primary and metastatic cancer.

Other bacteria-specific radiotracers, including antibiotics and specific metabolites, have been proposed for PET imaging to localize infections (3, 4). However, a major limitation of using antibiotic-based tracers lies in resistance to the antibiotic agent. If a microbe does not uptake and retain the antibiotic tracer, it is rendered useless. Does trimethoprim resistance limit using the 11C-trimethoprim tracer to detect bacterial infections? Lee, Jacome, and colleagues demonstrated that, despite trimethoprim resistance, medically relevant bacteria remained labeled with the antibiotic-based tracer (2). The investigators used whole-genome sequencing of clinically relevant bacterial isolates to show that the DHFR gene commonly exists in multiple copies, including variants that confer drug resistance alongside drug-sensitive variants. Although bacteria may have been phenotypically resistant to the trimethoprim, they continued to express the drug-sensitive enzyme and remained capable of binding the PET radiotracer.

While trimethoprim-based PET radiotracers open opportunities to detect deep invasive bacterial infections, barriers still exist that limit the more generalized use of these and other antibiotic-based radiotracers. Antibiotics have multiple specificities for different types and species of organisms that may influence the sensitivity and specificity of imaging different types of infections. Conversely, many antibiotics are nonspecific, taken up by multiple species of bacteria; this limits the ability of radiotracers to provide specific information about the exact etiology of an infection localized by PET or its antibiotic susceptibility profile. Thus, a positive PET scan using an antibiotic-based tracer may still require invasive sampling of the presumed infection to obtain prognostically and therapeutically important information. Despite these limitations, antibiotic-based PET radiotracers, such as those using trimethoprim, may provide an important tool for clinicians to noninvasively narrow the list of diagnoses and necessary diagnostic and therapeutic next steps.

Footnotes

Conflict of interest: The author has declared that no conflict of interest exists.

Copyright: © 2022, Seed et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Reference information: J Clin Invest. 2022;132(18):e162885. https://doi.org/10.1172/JCI162885.

See the related article at Imaging sensitive and drug-resistant bacterial infection with [11C]-trimethoprim.

References
  1. Kung BT, et al. An update on the role of 18F-FDG-PET/CT in major infectious and inflammatory diseases. Am J Nucl Med Mol Imaging. 2019;9(6):255–273.
    View this article via: PubMed Google Scholar
  2. Lee IK, et al. Imaging-sensitive and drug-resistant bacterial infection with [11C]-trimethoprim. J Clin Invest. 2022;132(18):e156679.
  3. Langer O, et al. In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET. Eur J Nucl Med Mol Imaging. 2005;32(2):143–150.
    View this article via: CrossRef PubMed Google Scholar
  4. Rubin RH, et al. Pharmacokinetics of fleroxacin as studied by positron emission tomography and [18F]fleroxacin. Am J Med. 1993;94(3a):31–37.
Version history
  • Version 1 (September 15, 2022): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 4
  • Article usage
  • Citations to this article (0)

Go to

  • Top
  • Footnotes
  • References
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 6 X users
1 readers on Mendeley
See more details
Posted by 13 X users
On 1 Facebook pages
16 readers on Mendeley
See more details